Trial Profile
Efficacy and safety of orexin receptor antagonist as premedication
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Pharmacodynamics
- 07 Dec 2015 Status changed from not yet recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 02 Dec 2015 New trial record